晚期非小細(xì)胞肺癌EGFR TKI獲得性耐藥的熱點(diǎn)研究及進(jìn)展 主要內(nèi)容 EGFR TKI作用機(jī)制 耐藥機(jī)制新藥臨床研究前景展望 EGFR ERBB3 AKT EGFR信號(hào)傳導(dǎo)的分子機(jī)制J EGFR GefitinibErlotinib EGFR TKI作用機(jī)制 主要內(nèi)容 EGFR TKI作用機(jī)制 耐藥機(jī)制新藥研究前景展望 EGFR TKI耐藥機(jī)制 49 5 3 2 11 23 2 3 T790 EGFR ERBB3 AKT T790 GefitinibErlotinib T790M介導(dǎo)EGFR TKI耐藥機(jī)制 EGFR TKI耐藥熱點(diǎn)研究梳理 EGFR tki耐藥 MET抑制劑 AfatinibDacomitinib C01686 Rociletinib RociletinibinEGFR MutatedNon Small CellLungCancer NCT01526928 NEnglJMed2015 372 1700 1709April30 2015DOI 10 1056 NEJMoa1413654 BestResponsetoRociletinib Eachbarrepresentsanindividualpatient andtheamplitudeanddirectionofthebarrepresentthepercentchangeintumorburdenduringtreatmentascomparedwithbaseline Tumorburdenwasmeasuredasthesumofthelongestdiametersofthetargetlesions accordingtotheResponseEvaluationCriteriainSolidTumors version1 1 Thedashedlineat20 representstheboundaryfordeterminationofprogressivedisease andthedashedlineat 30 representstheboundaryfordeterminationofpartialresponse FBdenotesfreebase andHBrhydrogenbromidesalt RociletinibinEGFR MutatedNon Small CellLungCancer NCT01526928 NEnglJMed 2015Apr30 372 18 1689 99 doi 10 1056 NEJMoa1411817 AZD9291inEGFRInhibitor ResistantNon Small CellLungCancer NCT01802632 AZD9291 AZD9291inEGFRInhibitor ResistantNon Small CellLungCancer NCT01802632 AZD9291inEGFRInhibitor ResistantNon Small CellLungCancer NCT01802632 AZD9291inEGFRInhibitor ResistantNon Small CellLungCancer NCT01802632 前景展望 3代TKI藥物應(yīng)用于耐藥的晚期NSCLC患者前景良好 期臨床試驗(yàn)已完成 期待 期臨床試驗(yàn)